Kevin Qing Shan - Publications

Affiliations: 
California Institute of Technology, Pasadena, CA 
Area:
Hippocampus

3/11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Shan KQ, Lubenov EV, Siapas AG. Model-based spike sorting with a mixture of drifting t-distributions. Journal of Neuroscience Methods. PMID 28652008 DOI: 10.1016/J.Jneumeth.2017.06.017  0.481
2016 Shan KQ, Lubenov EV, Papadopoulou M, Siapas AG. Spatial tuning and brain state account for dorsal hippocampal CA1 activity in a non-spatial learning task. Elife. 5. PMID 27487561 DOI: 10.7554/Elife.14321  0.564
2016 Shan KQ, Lubenov EV, Papadopoulou M, Siapas AG. Author response: Spatial tuning and brain state account for dorsal hippocampal CA1 activity in a non-spatial learning task Elife. DOI: 10.7554/Elife.14321.020  0.554
Low-probability matches (unlikely to be authored by this person)
2022 Vyas R, Gohel A, Escoffier C, Shan K, Katz J. Idiopathic lingual mandibular sequestration and its relationship to medication-related osteonecrosis of the jaws (MRONJ): mini review. Quintessence International (Berlin, Germany : 1985). 868-873. PMID 36169274 DOI: 10.3290/j.qi.b3418171  0.12
2012 Brand J, Kruczek N, Shan K, Haraf P, Simmons DE. Climbing for credit: applying Kurt Hahn's principles for promoting holistic lifestyles. Holistic Nursing Practice. 26: 103-5. PMID 22343932 DOI: 10.1097/HNP.0b013e31824733a3  0.049
2016 Halseth A, Shan K, Walsh B, Gilder K, Fujioka K. Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. Obesity (Silver Spring, Md.). PMID 28026920 DOI: 10.1002/oby.21726  0.032
2009 Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H, Koda JE, Weyer C. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring, Md.). 17: 1736-43. PMID 19521351 DOI: 10.1038/Oby.2009.184  0.024
2017 Guerdjikova AI, Walsh B, Shan K, Halseth AE, Dunayevich E, McElroy SL. Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study. Advances in Therapy. PMID 28918581 DOI: 10.1007/s12325-017-0613-9  0.02
2014 Herrmann K, Shan K, Brunell SC, Chen S. Effects of pramlintide in patients with type 2 diabetes mellitus: an analysis using daily insulin dose tertiles. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 20: 1070-5. PMID 25100363 DOI: 10.4158/EP13477.OR  0.01
2013 Herrmann K, Frias JP, Edelman SV, Lutz K, Shan K, Chen S, Maggs D, Kolterman OG. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. Postgraduate Medicine. 125: 136-44. PMID 23748514 DOI: 10.3810/pgm.2013.05.2635  0.01
2012 Malloy J, Gurney K, Shan K, Yan P, Chen S. Increased variability and abnormalities in pancreatic enzyme concentrations in otherwise asymptomatic subjects with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy. 5: 419-24. PMID 23269874 DOI: 10.2147/DMSO.S34241  0.01
Hide low-probability matches.